{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Graham ML"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Juvenile Diabetes Research Foundation United Kingdom"],"pagination":["745-760"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9832996"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(3)"],"pubmed_abstract":["A safe, efficacious, and clinically applicable immunosuppressive regimen is necessary for islet xenotransplantation to become a viable treatment option for diabetes. We performed intraportal transplants of wild-type adult porcine islets in 25 streptozotocin-diabetic cynomolgus monkeys. Islet engraftment was good in 21, partial in 3, and poor in 1 recipient. Median xenograft survival was 25 days with rapamycin and CTLA4Ig immunosuppression. Adding basiliximab induction and maintenance tacrolimus to the base regimen significantly extended median graft survival to 147 days (p < .0001), with three animals maintaining insulin-free xenograft survival for 265, 282, and 288 days. We demonstrate that this regimen suppresses non-Gal anti-pig antibody responses, circulating effector memory T cell exp"],"journal":["American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"],"pubmed_title":["Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques."],"pmcid":["PMC9832996"],"funding_grant_id":["7U19AI067151","21‐2006‐881","U19 AI067151"],"pubmed_authors":["Anazawa T","Ramachandran S","Singh A","Flanagan EB","Appakalai BN","Papas KK","Spizzo T","Bansal-Pakala P","Burlak C","Azimzadeh A","Martins K","Mueller KR","Hancock WW","Moore MEG","Schuurman HJ","Hering BJ","Murtaugh MP","Graham ML","O'Brien TD"],"additional_accession":[]},"is_claimable":false,"name":"Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques.","description":"A safe, efficacious, and clinically applicable immunosuppressive regimen is necessary for islet xenotransplantation to become a viable treatment option for diabetes. We performed intraportal transplants of wild-type adult porcine islets in 25 streptozotocin-diabetic cynomolgus monkeys. Islet engraftment was good in 21, partial in 3, and poor in 1 recipient. Median xenograft survival was 25 days with rapamycin and CTLA4Ig immunosuppression. Adding basiliximab induction and maintenance tacrolimus to the base regimen significantly extended median graft survival to 147 days (p < .0001), with three animals maintaining insulin-free xenograft survival for 265, 282, and 288 days. We demonstrate that this regimen suppresses non-Gal anti-pig antibody responses, circulating effector memory T cell exp","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T21:43:40.927Z","creation":"2025-04-04T21:43:40.927Z"},"accession":"S-EPMC9832996","cross_references":{"pubmed":["34704345"],"doi":["10.1111/ajt.16876"]}}